Prevention of analgesic abuse

• US 4,457,933 A
• Filed: 12/11/1981
• Issued: 07/03/1984
• Est. Priority Date: 01/24/1980
• Status: Expired due to Fees

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Gordon, Maxwell, Pachter, Irwin J.
• Primary Examiner(s): ORE, DALE
• Application Number:
  US06/329,839
• Time in Patent Office: 935 Days
• Field of Search: 424/260
• US Class Current: 514/282
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine

Abstract

This invention concerns a method for decreasing both the oral and parenteral abuse potential of strong analgetic agents such as oxycodone, propoxyphene and pentazocine by combining an analgesic dose of the analgetic agents with naloxone in specific, relatively narrow ranges. Oxycodone-naloxone compositions having a ratio of 2.5-5:1 parts by weight and pentazocine-naloxone compositions having a ratio of 16-50:1 parts by weight are preferred.

Claims

1. A method for decreasing the potential for oral abuse of an analgesic dose of oxycodone orally administered to a human comprising orally administering an oxycodone-naloxone composition having a ratio of 2.5-5:

1 parts by weight wherein said composition contains from 1 to 3 mg of naloxone.

2. The method of claim 1 wherein the oxycodone-naloxone composition contains from 1.4 to 2.5 mg of naloxone.

3. The method of claim 1 wherein the oxycodone-naloxone composition has a ratio of 3:

1 to 4;

1 parts by weight.

4. The method of claim 1 wherein the oxycodone-naloxone composition has a ratio of 3.5:

1 parts by weight.

5. The method of claim 1 wherein the oxycodone-naloxone composition has a ratio of 3.5:

1 parts by weight and contains from 1.4 to 2.5 mg of naloxone.

6. The method of claim 1 wherein the oxycodone-naloxone composition contains from 2.5 to 10 mg of oxycodone and from 1 to 3 mg of naloxone.

7. A method for decreasing the potential for oral abuse of an analgesic dose of pentazocine orally administered to a human comprising orally administering a pentazocine-naloxone composition having a ratio of 16-50:

1 parts by weight wherein said composition contains from 1 to 3 mg of naloxone.

8. The method of claim 7 wherein the pentazocine-naloxone composition contains from 1.4 to 2.5 mg of naloxone.

9. The method of claim 7 wherein the pentazocine-naloxone composition has a ratio of 20-40:

1 parts by weight.

10. The method of claim 7 wherein the pentazocine-naloxone composition has a ratio of 25:

1 parts by weight and contains from 1.4 to 2.5 mg of naloxone.

11. The method of claim 7 wherein the pentazocine-naloxone composition contains from 25-100 mg of pentazocine and from 1 to 3 mg of naloxone.